Medicare for Obesity Drugs Is Tricky --- Coverage for weight-loss drugs is a win for patients, but the math is more complicated for Wall Street

 

“Medicare began covering weight-loss drugs for seniors. For patients long shut out from the GLP-1 boom, the opening is a real milestone. For Wall Street, it isn't the windfall the headlines suggest.

Drugs such as Wegovy and Zepbound are used by millions of Americans. But federal law bars Medicare from paying for medications used for weight control. So many seniors unable to afford the drugs have been left behind.

For Eli Lilly and Novo Nordisk, the makers of Zepbound and Wegovy, Medicare was always a big prize: the nation's largest pool of drug demand, and the one big market obesity treatment couldn't reach. But for now the payoff to them will be slow and hard.

By some estimates, as many as 20 million U.S. seniors are overweight or obese.

But the pool that might gain access through Medicare's new pathway, known as Bridge, is far smaller. The program, which lets eligible seniors get the drugs for a $50 monthly copay, is temporary, and its rules are tighter than the drugs' Food and Drug Administration approvals, requiring a higher weight threshold or a serious related condition.

Anyone receiving GLP-1 coverage through standard Medicare drug benefits, for diabetes, sleep apnea or related conditions, is excluded.

Run those filters and the number looks modest. KFF, a nonpartisan health-research group, mapped Medicare claims and estimated 3.8 million seniors eligible, out of more than 13 million who are overweight or obese. The agency agrees: Its Medicare director, Chris Klomp, said the program would start in the "single-digit millions."

The revenue math follows from there. Evan Seigerman, an analyst at BMO Capital Markets, pegs the near-term opportunity at roughly $3 billion a year in added sales, assuming modest uptake. Push participation up, and the figure could be higher. Those numbers aren't trivial, but it takes a lot to make a significant difference for two companies whose combined annual GLP-1 sales are running north of $80 billion.

And even the modest case assumes a clean rollout, something new government programs rarely deliver. Doctors must attest that patients meet strict criteria. Pharmacies must route claims through unfamiliar channels. As Scott Kahan, director of the National Center for Weight and Wellness, puts it, expect confusion and hiccups at the outset.

Then comes the part that is harder to predict. The program exists only because the government designed it as a temporary workaround to a law that bars Medicare from covering weight loss. It was meant to be brief, a six-month on-ramp to a permanent, insurer-run benefit through Medicare's Part D drug plans, called Balance.

But the plan to hand it off for 2027 fell apart. Too few private plans agreed to take on the cost, and in April the government shelved Balance indefinitely, extending the intended timeline for Bridge and continuing to foot the bill through 2027. Insurers could step in for 2028, but nothing compels them to, and they balked once for a simple reason: Covering this category pushes premiums higher for everyone.

Unless that math changes, Kahan said, this risks becoming a bridge to nowhere. What could rescue it, he said, is proof the drugs pay for themselves through better health and lower downstream costs.

Longer term, the opportunity could grow into something meaningful, Seigerman said, and if uptake outruns expectations, there is real upside. But that same uncertainty cuts the other way. It is hard to build a clean model around a policy that could quietly become permanent, or disappear in its current form.

The program is a crucial door opening as some are quietly closing. Commercial coverage of these drugs for obesity, a major engine of their growth, has begun to retreat. More than a quarter of big companies say they are adding criteria this year or next, while many others are planning to drop coverage for weight-loss purposes.

Bridge represents modest revenue today, but government support could become crucial for weight-loss drug providers and patients. For Wall Street, this is a variable to watch, not yet one to bank on.” [1]

 

1. Medicare for Obesity Drugs Is Tricky --- Coverage for weight-loss drugs is a win for patients, but the math is more complicated for Wall Street. Wainer, David.  Wall Street Journal, Eastern edition; New York, N.Y.. 03 July 2026: B10.